Finn Jonathan 4

What Happened

• Finn Jonathan, a director of Atossa Therapeutics, received a grant of 10,000 restricted stock units (RSUs) on 2026-05-12. The RSUs were granted at $0.00 per share (no cash paid) and therefore have a transaction cost of $0 on the grant date. Each RSU represents a contingent right to one share of common stock and will vest on the first anniversary (May 12, 2027).

Key Details

• Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (appears timely).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 10,000 RSUs; grant price reported $0.00; reported value at grant not stated in filing.
• Vesting: RSUs vest on May 12, 2027 (per footnote F1).
• Shares owned after transaction: Not disclosed in the summary data provided.
• Footnote: F1 explains each RSU is a contingent right to one share and vests on the first anniversary; no tax-withholding or 10b5-1 plan noted.

Context

• RSU grants are common compensation/retention tools for directors and executives and do not represent an immediate purchase or sale of stock. The grant is a neutral-to-mildly-bullish signal insofar as it aligns the director’s incentives with shareholders over the vesting period, but it does not indicate an immediate cash outlay or market action. The economic value will depend on Atossa’s share price at vesting.